Mochi names women's conditions in its materials, and after years of being handed advice written for someone else that acknowledgement is not nothing. It is a reasonable reason to look.
This page is about what sits behind the naming. The programme is not built around a whole-person or gynecologic history, and once you follow that through, the recognition turns out to live in the marketing rather than in how care is actually organised.
Here is how Mochi Health reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
Care is delivered through an app at $278 a month with 503A compounding available. The structure runs on plan tiers, which means your dose is set by which plan you are on rather than by how you are responding — so the 503A capability does not become individualised dosing the way it does elsewhere. That is why dose fit scores zero despite the compounding being there.
Five of seven Charter rows score zero here, the widest set of blanks on the page: no whole-person framing, no dose responsiveness, no published support commitment, no lasting-care plan and no cost clarity ahead of enrolling. Being believed scores partial on the strength of women's conditions being named. At $278 that is a considerable amount of money for a structure this thin.
Put these to Mochi Health in writing, and keep the reply.
Mochi rates at the bottom of this Charter because the Charter measures what is built rather than what is named. The recognition is real and worth something. It is not the same as care organised around the person.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.